Association of cannabis potency with mental ill health and addiction: a systematic review

  • 1.

    World Drug Report 2021.

    United Nations,
    2021

  • 2.
    • Hanuš LO
    • Meyer SM
    • Muñoz E
    • Taglialatela-Scafati O
    • Appendino G

    Phytocannabinoids: a unified critical inventory.

    Nat Prod Rep. 2016; 33: 1357-1392

  • 3.
    • Curran HV
    • Freeman TP
    • Mokrysz C
    • Lewis DA
    • Morgan CJA
    • Parsons LH

    Keep off the grass? Cannabis, cognition and addiction.

    Nat Rev Neurosci. 2016; 17: 293-306

  • 4.
    • Curran HV
    • Brignell C
    • Fletcher S
    • Middleton P
    • Henry J

    Cognitive and subjective dose-response effects of acute oral Δ 9-tetrahydrocannabinol (THC) in infrequent cannabis users.

    Psychopharmacology. 2002; 164: 61-70

  • 5.
    • D’Souza DC
    • Perry E
    • MacDougall L
    • et al.

    The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis.

    Neuropsychopharmacology. 2004; 29: 1558-1572

  • 6.
    • Freeman TP
    • Craft S
    • Wilson J
    • et al.

    Changes in delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) concentrations in cannabis over time: systematic review and meta-analysis.

    Addiction. 2021; 116: 1000-1010

  • 7.
    • Chandra S
    • Radwan MM
    • Majumdar CG
    • Church JC
    • Freeman TP
    • ElSohly MA

    New trends in cannabis potency in USA and Europe during the last decade (2008–2017).

    Eur Arch Psychiatry Clin Neurosci. 2019; 269: 5-15

  • 8.
    • Smart R
    • Caulkins JP
    • Kilmer B
    • Davenport S
    • Midgett G

    Variation in cannabis potency and prices in a newly legal market: evidence from 30 million cannabis sales in Washington state.

    Addiction. 2017; 112: 2167-2177

  • 9.
    • Marconi A
    • Di Forti M
    • Lewis CM
    • Murray R
    • Vassios E

    Meta-analysis of the association between the level of cannabis use and risk of psychosis.

    Schizophr Bull. 2016; 42: 1262-1269

  • 10.
    • Lev-Ran S
    • Roerecke M
    • Le Foll B
    • George T
    • McKenzie K
    • Rehm J

    The association between cannabis use and depression: a systematic review and meta-analysis of longitudinal studies.

    Psychol Med. 2014; 44: 797-810

  • 11.
    • Xue S
    • Husain MI
    • Zhao H
    • Ravindran AV

    Cannabis use and prospective long-term association with anxiety: a systematic review and meta-analysis of longitudinal studies: Usage du cannabis et association prospective à long terme avec l’anxiété: une revue systématique et une méta-analyse d’études longitudinales.

    Can J Psychiatry. 2021; 66: 126-138

  • 12.
    • Leung J
    • Chan GCK
    • Hides L
    • Hall WD

    What is the prevalence and risk of cannabis use disorders among people who use cannabis? A systematic review and meta-analysis.

    Addict Behav. 2020; 109106479

  • 13.
    • Di Forti M
    • Marconi A
    • Carra E
    • et al.

    Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study.

    Lancet Psychiatry. 2015; 2: 233-238

  • 14.

    Examining the profile of high-potency cannabis and its association with severity of cannabis dependence.

    Psychol Med. 2015; 45: 3181-3189

  • 15th.
    • Chan GCK
    • Hall W
    • Freeman TP
    • Ferris J
    • Kelly AB
    • Winstock A

    User characteristics and effect profile of butane hash oil: an extremely high-potency cannabis concentrate.

    Drug Alcohol Depend. 2017; 178: 32-38

  • 16.
    • Page MJ
    • McKenzie JE
    • Bossuyt PM
    • et al.

    The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.

    BMJ. 2021; 372: n71

  • 17.
    • Mateen FJ
    • Oh J
    • Tergas AI
    • Bhayani NH
    • Kamdar BB

    Titles versus titles and abstracts for initial screening of articles for systematic reviews.

    Clin Epidemiol. 2013; 5: 89-95

  • 18.Higgins JPT Thomas J Chandler J Cochrane handbook for systematic reviews of interventions. John Wiley & Sons,
    Chichester2019
  • 19.
    • Di Forti M
    • Morgan C
    • Dazan P
    • et al.

    High-potency cannabis and the risk of psychosis.

    Br J Psychiatry. 2009; 195: 488-491

  • 20.
    • Di Forti M
    • Sallis H
    • Allegri F
    • et al.

    Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users.

    Schizophr Bull. 2014; 40: 1509-1517

  • 21.
    • Sideli L
    • Fisher HL
    • Murray R
    • et al.

    Interaction between cannabis consumption and childhood abuse in psychotic disorders: preliminary findings on the role of different patterns of cannabis use.

    Early Interv Psychiatry. 2018; 12: 135-142

  • 22.
    • Di Forti M
    • Quattrone D
    • Freeman TP
    • et al.

    The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study.

    Lancet Psychiatry. 2019; 6: 427-436

  • 23.
    • Quattrone D
    • Ferraro L
    • Tripoli G
    • et al.

    Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: the EU-GEI case-control study.

    Psychol Med. 2020; 51: 1-9

  • 24.
    • Schoeler T
    • Petros N
    • Di Forti M
    • et al.

    Effects of continuation, frequency, and type of cannabis use on relapse in the first 2 years after onset of psychosis: an observational study.

    Lancet Psychiatry. 2016; 3: 947-953

  • 25.

    Examining links between cannabis potency and mental and physical health outcomes.

    Behav Res Ther. 2019; 115: 111-120

  • 26.
    • Matsumoto T
    • Kawabata T
    • Okita K
    • et al.

    Risk factors for the onset of dependence and chronic psychosis due to cannabis use: survey of patients with cannabis-related psychiatric disorders.

    Neuropsychopharmacol Rep. 2020; 40: 332-341

  • 27.
    • Hines LA
    • Freeman TP
    • Gage SH
    • et al.

    Association of high-potency cannabis use with mental health and substance use in adolescence.

    JAMA Psychiatry. 2020; 77: 1044-1051

  • 28.

    A within-person comparison of the subjective effects of higher vs. lower-potency cannabis.

    Drug Alcohol Depend. 2020; 216108225

  • 29.
    • Bidwell LC
    • YorkWilliams SL
    • Mueller RL
    • Bryan AD
    • Hutchison KE

    Exploring cannabis concentrates on the legal market: user profiles, product strength, and health-related outcomes.

    Addict Behav Rep. 2018; 8: 102-106

  • 30.
    • Craft S
    • Winstock A
    • Ferris J
    • Mackie C
    • Lynskey MT
    • Freeman TP

    Characterizing heterogeneity in the use of different cannabis products: latent class analysis with 55 000 people who use cannabis and associations with severity of cannabis dependence.

    Psychol Med. 2020; 50: 2364-2373

  • 31.
    • Brunt T
    • van Genugten M
    • Höner-Snoeken K
    • van de Velde MJ
    • Niesink RJM

    Therapeutic satisfaction and subjective effects of different strains of pharmaceutical-grade cannabis.

    J Clin Psychopharmacol. 2014; 34: 344-349

  • 32.
    • Wan BA
    • Diaz P
    • Chan S
    • et al.

    Efficacy of different varieties of medical cannabis in relieving symptoms.

    J Pain Manag. 2017; 10: 375-383

  • 33.
    • Cutler C
    • Spradlin A
    • McLaughlin RJ

    A naturalistic examination of the perceived effects of cannabis on negative affect.

    J Affect Disord. 2018; 235: 198-205

  • 34.
    • Stith SS
    • Li X
    • Diviant JP
    • et al.

    The effectiveness of inhaled Cannabis flower for the treatment of agitation/irritability, anxiety, and common stress.

    J Cannabis Res. 2020; 2: 47

  • 35.
    • Li X
    • Diviant JP
    • Stith SS
    • et al.

    The effectiveness of Cannabis flower for immediate relief from symptoms of depression.

    Yale J Biol Med. 2020; 93: 251-264

  • 36.
    • Tanda G
    • Munzar P
    • Goldberg SR

    Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys.

    Nat Neurosci. 2000; 3: 1073-1074

  • 37.
    • Justinova Z
    • Tanda G
    • Redhi GH
    • Goldberg SR

    Self-administration of delta9-tetrahydrocannabinol (THC) by drug naive squirrel monkeys.

    Psychopharmacology. 2003; 169: 135-140

  • 38.
    • Freeman TP
    • van der Pol P
    • Kuijpers W
    • et al.

    Changes in cannabis potency and first-time admissions to drug treatment: a 16-year study in the Netherlands.

    Psychol Med. 2018; 48: 2346-2352

  • 39.
    • Freeman TP
    • Morgan CJ
    • Hinducha C
    • Schafer G
    • Das RK
    • Curran HV

    Just say ‘know’: how do cannabinoid concentrations influence users’ estimates of cannabis potency and the amount they roll in joints?.

    Addiction. 2014; 109: 1686-1694

  • 40.
    • van der Pol P
    • Liebregts N
    • de Graaf R
    • Korf DJ
    • van den Brink W
    • van Laar M

    Validation of self-reported cannabis dose and potency: an ecological study.

    Addiction. 2013; 108: 1801-1808

  • 41.
    • Leung J
    • Stjepanovic D
    • Dawson D
    • Hall WD

    Do cannabis users reduce their THC dosages when using more potent cannabis products? A review.

    Front Psychiatry. 2021; ()

  • 42.
    • Lorenzetti V
    • Chandni H
    • Petrilli K
    • et al.

    The International Cannabis Toolkit (iCannToolkit): a multidisciplinary expert consensus on minimum standards for measuring cannabis use.

    Addiction. 2021; 117: 1510-1517

  • 43.

    ‘Standard THC units’: a proposal to standardize dose across all cannabis products and methods of administration.

    Addiction. 2020; 115: 1207-1216

  • 44.
    • Freeman AM
    • Petrilli K
    • Lees R
    • et al.

    How does cannabidiol (CBD) influence the acute effects of delta-9-tetrahydrocannabinol (THC) in humans? A systematic review.

    Neurosci Biobehav Rev. 2019; 107: 696-712

  • 45.
    • Fischer B
    • Russell C
    • Sabioni P
    • et al.

    Lower-risk cannabis use guidelines: a comprehensive update of evidence and recommendations.

    Am J Public Health. 2017; 107: e1-12

  • Leave a Comment